Fig. 1

Optimization of ASX encapsulation and characterization of LPs. (A) Schematic diagram of Lf-ASX-LP preparation. EE and LC of ASX-LPs were measured under varying (B) ASX-to-lipid ratios and (C) lipid compositions. (D) Concentration of conjugated Lf on LPs under varying initial concentrations of Lf. (E) Average particle size, PDI, and (F) zeta potential of each formulation. (G) Topographic images of Lf-ASX-LPs obtained by AFM